RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Loncar launched its China BioPharma ETF, a fund that gives international investors access to a diversified portfolio of China-based innovative biopharmas. The exchange-traded-fund currently holds 28 companies, made up of China-centered biopharmas that are traded in Hong Kong (22) and on the NASDAQ exchange (6). The fund mirrors the Loncar China BioPharma Index, which was announced in March of this year. The fund’s three largest holdings are WuXi Biologics, Shanghai Fosun Pharma and Sino Biopharmaceuticals.
Source: China Biotoday
